Day Two

Leading industry leaders in the agbiotech space unite to reflect on the current state of the agbiologicals market, to identify what’s working, where challenges remain, and how the space is evolving. Drawing on real-world experience, the discussion will explore the key forces shaping growth today and offer perspectives on what the market is likely to look like in the years ahead. This conversation sets the scene for the deeper technical, regulatory, and commercial sessions to follow.

This dynamic session offers a platform for early-stage microbiome companies to pitch their technologies to a panel of investors, pharma scouts, and industry experts. Designed to foster visibility, feedback, and potential partnerships, each presentation is followed by live commentary and audience engagement.

Please reach out via the sponsor@hansonwade.com email to get involved

• Analyzing environmental and field-level data to match precision microbial solutions
• Integrating field imaging and machine learning to optimize treatment performance
• Predicting field outcomes while managing data variability and quality challenges 

• Mapping field-level data to real application decisions
• Using AI tools to predict performance across varying environmental conditions
• Lessons learned from deploying AI unstructured field data

As agbiological research faces increasing pressure to deliver faster results at lower cost, trust and scientific credibility remain critical. This roundtable explores how advances in AI are enabling more reliable, unbiased, and reproducible research outcomes, helping laboratories reduce variability, limit reliance on extensive field trials, and accelerate decision-making without compromising integrity.

• Discuss how AI improves trust and reproducibility in biostimulant research
• Reduce bias and variability while increasing speed and efficiency
• Hear real-world applications of AI in microbiome and agbiotech R&D

• Evaluating scientific credibility, field relevance, and customer trust as go and/or no-go criteria
• Applying early microbiome analysis to focus development on products that work under real grower conditions
• Balancing innovation with commercial risk when choosing what moves from R&D into product pipelines

• Identifying the most common scale-up, manufacturing, and market-entry failures seen in commercial programs
• Aligning formulation, production, and field performance with buyer expectations and regional constraints
• Differentiating products in crowded markets by targeting unmet needs and defensible value propositions

•  Integrating soil microbiome, metabolomic, and physicochemical data to define functional soil health indicators
• Linking biological community shifts to nutrient cycling, root uptake efficiency, and disease suppression
• Validating soil health metrics through replicated field trials and longitudinal measurements

• Debating how soil health metrics, microbial community data, and agronomic measurements should be used to define efficacy
• Examining why biological products succeed in some regions and fail in others, and how to design trials that capture context
• Discussing what localized data, field evidence, and success thresholds growers need to trust and adopt biological inputs